|
| Status |
Public on Sep 23, 2017 |
| Title |
Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology |
| Platform organism |
Rubella virus vaccine strain RA27/3 |
| Sample organism |
Homo sapiens |
| Experiment type |
Protein profiling by protein array
|
| Summary |
This study uses proteome microarray technology/data to identify predictive biomarkers of neutralizing antibody response and potential new correlates of protective immunity in rubella virus serology.
|
| |
|
| Overall design |
In the study presented here, a well-characterized cohort of 75 high and 75 low rubella virus-specific neutralizing antibody responders after two MMR vaccine doses was used to acquire microarray antibody measurements to all rubella virus proteins. These data were used in multivariate penalized logistic regression modeling of rubella-specific neutralizing antibody response after vaccination.
|
| |
|
| Contributor(s) |
Haralambieva IH, Gibson MJ, Kennedy RB, Ovsyannikova IG, Warner ND, Grill DE, Poland GA |
| Citation(s) |
29145521 |
| |
| Submission date |
Sep 22, 2017 |
| Last update date |
Jan 24, 2018 |
| Contact name |
Gregory A. Poland, M.D. |
| E-mail(s) |
poland.gregory@mayo.edu
|
| Organization name |
Mayo Clinic
|
| Lab |
Vaccine Research Group
|
| Street address |
200 1st St SW
|
| City |
Rochester |
| State/province |
MN |
| ZIP/Postal code |
55905 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24038 |
Rubella virus-specific proteome microarray chip (Antigen Discovery, Inc., Irvine, CA) |
|
| Samples (150)
|
|
| Relations |
| BioProject |
PRJNA411822 |
Less...
More...